Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365684 | 0.78 | ATM (0.37) | — | |
| SCHEMBL14344241 | 0.77 | KMT2A (0.46) | CYP1A2CYP2A6 | |
| SCHEMBL15024629 | 0.75 | CA12 (0.37) | — | |
| SCHEMBL2776654 | 0.74 | TDP1 (0.33) | — | |
| SCHEMBL6424657 | 0.74 | ALDH1A1 (0.38) | — | |
| SCHEMBL8785577 | 0.71 | KMT2A (0.57) | CYP1A2CYP2A6 | |
| SCHEMBL8784742 | 0.71 | KMT2A (0.57) | CYP1A2CYP2A6 | |
| SCHEMBL2776266 | 0.70 | CA12 (0.39) | — | |
| SCHEMBL5451536 | 0.66 | KDM4E (0.38) | CYP1A2CYP2A6 | |
| SCHEMBL5460331 | 0.66 | ALDH1A1 (0.37) | CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989451-B2 | Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-08-02 | — | — | US | disclosed |
| US-7816521-B2 | 1,2,4-benzotriazine-1,4-dioxides | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-10-19 | — | — | US | disclosed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | disclosed |
| US-20070197534-A1 | Novel 1,2,4-benzotriazine-1,4-dioxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197534-A1 | Novel 1,2,4-benzotriazine-1,4-dioxides | HIF1AN, HIF1A, HYOU1 | CYP1A2 1112/4885CYP2A6 1882/4885 |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | HIF1AN, HIF1A, HYOU1 | CYP1A2 42/4885CYP2A6 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.